Race Oncology (ASX:RAC) began patient enrollment at Southside Cancer Care Center in Miranda, New South Wales for the Phase 1 clinical trial of RC220 in advanced solid tumors, according to a Thursday filing with the Australian bourse.
It will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose in combination with doxorubicin, and effects on a range of clinical biomarkers, the filing stated.
The open-label phase one trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, per the filing.
Race Oncology's shares were up 6% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.